Human CD4/CD4mut ORF/cDNA clone-Lentivirus plasmid (BC025782)

Cat. No.: pGMLP004095
Size: 10 µg
Concentration: generally 0.5ug/ul, usually not less than 0.3ug/ul
Leading Time: 3-7 working days

Pre-made Human CD4/CD4mut Lentiviral expression plasmid for CD4 lentivirus packaging, CD4 lentivirus production, overexpression stable cell line development, cell transient transfection and gene delivery targeting T/B/NK cells, macrophages, cardiomyocytes, hepatocytes, and neurons.

Our GM-Lentiviral vector is seamlessly integrated with the GM lentivirus packaging system. Discover more about the GM lentivirus packaging system.

pdf Datasheet
pdf MSDS
pdf Terms of Use
Target products collection

Go to CD4/CD4mut products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

Purchase
Total Price: $685.56
Shipping fee: Limited-time free
For payment issues, contact us.


Product Description

Catalog ID pGMLP004095
Gene Name CD4
Accession Number BC025782
Gene ID 920
Species Human
Product Type Lentivirus plasmid (overexpression)
Insert Length 1377 bp
Gene Alias CD4mut
Fluorescent Reporter ZsGreen
Mammalian Cell Selection Puromyocin
Fusion Tag 3xflag (C-Terminal)
Promoter CMV
Resistance Amplicin
ORF Nucleotide Sequence ATGAACCGGGGAGTCCCTTTTAGGCACTTGCTTCTGGTGCTGCAACTGGCGCTCCTCCCAGCAGCCACTCAGGGAAAGAAAGTGGTGCTGGGCAAAAAAGGGGATACAGTGGAACTGACCTGTACAGCTTCCCAGAAGAAGAGCATACAATTCCACTGGAAAAACTCCAACCAGATAAAGATTCTGGGAAATCAGGGCTCCTTCTTAACTAAAGGTCCATCCAAGCTGAATGATCGCGCTGACTCAAGAAGAAGCCTTTGGGACCAAGGAAACTTTCCCCTGATCATCAAGAATCTTAAGATAGAAGACTCAGATACTTACATCTGTGAAGTGGAGGACCAGAAGGAGGAGGTGCAATTGCTAGTGTTCGGATTGACTGCCAACTCTGACACCCACCTGCTTCAGGGGCAGAGCCTGACCCTGACCTTGGAGAGCCCCCCTGGTAGTAGCCCCTCAGTGCAATGTAGGAGTCCAAGGGGTAAAAACATACAGGGGGGGAAGACCCTCTCCGTGTCTCAGCTGGAGCTCCAGGATAGTGGCACCTGGACATGCACTGTCTTGCAGAACCAGAAGAAGGTGGAGTTCAAAATAGACATCGTGGTGCTAGCTTTCCAGAAGGCCTCCAGCATAGTCTATAAGAAAGAGGGGGAACAGGTGGAGTTCTCCTTCCCACTCGCCTTTACAGTTGAAAAGCTGACGGGCAGTGGCGAGCTGTGGTGGCAGGCGGAGAGGGCTTCCTCCTCCAAGTCTTGGATCACCTTTGACCTGAAGAACAAGGAAGTGTCTGTAAAACGGGTTACCCAGGACCCTAAGCTCCAGATGGGCAAGAAGCTCCCGCTCCACCTCACCCTGCCCCAGGCCTTGCCTCAGTATGCTGGCTCTGGAAACCTCACCCTGGCCCTTGAAGCGAAAACAGGAAAGTTGCATCAGGAAGTGAACCTGGTGGTGATGAGAGCCACTCAGCTCCAGAAAAATTTGACCTGTGAGGTGTGGGGACCCACCTCCCCTAAGCTGATGCTGAGCTTGAAACTGGAGAACAAGGAGGCAAAGGTCTCGAAGCGGGAGAAGGCGGTGTGGGTGCTGAACCCTGAGGCGGGGATGTGGCAGTGTCTGCTGAGTGACTCGGGACAGGTCCTGCTGGAATCCAACATCAAGGTTCTGCCCACATGGTCCACCCCGGTGCAGCCAATGGCCCTGATTGTGCTGGGGGGCGTCGCCGGCCTCCTGCTTTTCATTGGGCTAGGCATCTTCTTCTGTGTCAGGTGCCGGCACCGAAGGCGCCAAGCAGAGCGGATGTCTCAGATCAAGAGACTCCTCAGTGAGAAGAAGACCTGCCAGTGCCCTCACCGGTTTCAGAAGACATGTAGCCCCATTTGA
ORF Protein Sequence MNRGVPFRHLLLVLQLALLPAATQGKKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICEVEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPSVQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKKVEFKIDIVVLAFQKASSIVYKKEGEQVEFSFPLAFTVEKLTGSGELWWQAERASSSKSWITFDLKNKEVSVKRVTQDPKLQMGKKLPLHLTLPQALPQYAGSGNLTLALEAKTGKLHQEVNLVVMRATQLQKNLTCEVWGPTSPKLMLSLKLENKEAKVSKREKAVWVLNPEAGMWQCLLSDSGQVLLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIGLGIFFCVRCRHRRRQAERMSQIKRLLSEKKTCQCPHRFQKTCSPI

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Biosimilar GMP-Bios-ab-640 Pre-Made Zanolimumab biosimilar, Whole mAb, Anti-CD4 Antibody: Anti-IMD79/OKT4D therapeutic antibody
    Biosimilar GMP-Bios-INN-965 Pre-Made Priliximab Biosimilar, Whole Mab, Anti-Cd4 Antibody: Anti-IMD79/OKT4D therapeutic antibody
    Biosimilar GMP-Bios-INN-782 Pre-Made Clenoliximab Biosimilar, Whole Mab, Anti-Cd4 Antibody: Anti-IMD79/OKT4D therapeutic antibody
    Biosimilar GMP-Bios-ab-257 Pre-Made Ibalizumab biosimilar, Whole mAb, Anti-CD4 Antibody: Anti-IMD79/OKT4D therapeutic antibody
    Biosimilar GMP-Bios-INN-881 Pre-Made Keliximab Biosimilar, Whole Mab, Anti-Cd4 Antibody: Anti-IMD79/OKT4D therapeutic antibody
    Biosimilar GMP-Bios-ab-594 Pre-Made Tregalizumab biosimilar, Whole mAb, Anti-CD4 Antibody: Anti-IMD79/OKT4D therapeutic antibody
    Biosimilar GMP-Bios-INN-773 Pre-Made Cedelizumab Biosimilar, Whole Mab, Anti-Cd4 Antibody: Anti-IMD79/OKT4D therapeutic antibody
    Target Antibody GM-Tg-g-T10191-Ab Anti-CD4/ CD4mut monoclonal antibody
    Target Antigen GM-Tg-g-T10191-Ag CD4 VLP (virus-like particle)
    ORF Viral Vector pGMLP004095 Human CD4 Lentivirus plasmid
    ORF Viral Vector pGMAP000215 Human CD4 Adenovirus plasmid
    ORF Viral Vector vGMLP004095 Human CD4 Lentivirus particle
    ORF Viral Vector vGMAP000215 Human CD4 Adenovirus particle


    Target information

    Target ID GM-T10191
    Target Name CD4
    Gene Group Identifier
    （Target Gene ID in Homo species)         		920
    Gene ID 100052502 (Equus caballus), 12504 (Mus musculus), 24932 (Rattus norvegicus), 403931 (Canis lupus familiaris)
    407098 (Bos taurus), 493775 (Felis catus), 713807 (Macaca mulatta), 920 (Homo sapiens)
    Gene Symbols & Synonyms CD4,Cd4,L3T4,Ly-4,p55,W3/25,T4,IMD79,Leu-3,OKT4D,CD4mut
    Target Alternative Names CD4,CD4mut,Cd4,IMD79,L3T4,Leu-3,Ly-4,OKT4D,T-cell surface antigen T4/Leu-3,T-cell surface glycoprotein CD4,T4,W3/25,p55
    Uniprot Accession P01730,P05540,P06332,P16003,P33705
    Additional SwissProt Accessions: P06332,P05540,P33705,P16003,P01730
    Uniprot Entry Name
    Protein Sub-location Transmembrane Protein
    Category Therapeutics Target, Immuno-oncology Target, INN Index
    Disease
    Disease from KEGG Cytokine-cytokine receptor interaction, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Yersinia infection, Human T-cell leukemia virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer
    Gene Ensembl ENSECAG00000009049, ENSMUSG00000023274, ENSCAFG00845027739, ENSBTAG00000003255, ENSMMUG00000013202, ENSG00000010610
    Target Classification Checkpoint-Immuno Oncology


    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.